Several factors have been responsible for pushing the total market cap of cryptocurrencies higher. Shutterstock
The total market capitalization (market cap) of cryptocurrencies continues to grow, recently surpassing $170 billion and hitting a fresh, record high.
The total market cap of these digital assets rose to as much as $172.2 billion earlier today, according to CoinMarketCap.
This figure represents a more than 850% increase from their value of $17.7 billion at the start of this year.
Why does this innovative asset class continue to grow?
The crypto market is growing for several reasons, according to analysts.
A steady supply of Initial Coin Offerings (ICOs), a rising number of funds that trade cryptocurrencies and the sustained interest of investors are all contributing to this trend.
great stocks to own: Alexco Resource Corp(AXU)
- [By Cameron Saucier]
Alexco Resource (NYSEMKT: AXU) operates in two segments: an environmental services business and a mining company. Its mining segment explores developments in Canada, while its environmental segment provides consulting and project management services in the United States and Canada. AXU is up over 400% YTD. The stock has been steadily rising since January. It isn’t clear what’s driving AXU upwards, other than general investor speculation. The stock is trading at $1.72 per share as of Monday intraday.
great stocks to own: Actinium Pharmaceuticals, Inc.(ATNM)
- [By Lisa Levin]
Shares of Actinium Pharmaceuticals Inc (NYSE: ATNM) were down 24 percent to $1.29. Actinium priced 8 million shares at $1.25 per share.
Shineco Inc (NASDAQ: TYHT) was down, falling around 32 percent to $19.50. On Wednesday, Shineco priced IPO at $4.50 per share.
great stocks to own: HP Inc.(HPQ)
- [By Matt Hogan]
Apple EBITDA Margins vs Peers Chart Apple's EBITDA margins vs technology peers: Western Digital Corp. (NASDAQ: WDC), HP Inc. (NYSE: HPQ), Hewlett Packard Enterprise Co. (NYSE: HPE) and NetApp Inc. (NASDAQ: NTAP).
- [By Anders Bylund]
Shares of HP Inc. (NYSE:HPQ) rose 15.4% in February 2017, according to data from S&P Global Market Intelligence.
The big jump came late in the month. HP reported first-quarter 2017 results on Feb. 22, leaving Wall Street’s estimates far behind despite modest revenue growth and flat earnings. Investors chose to ignore a gloomy slate of second-quarter guidance targets, and share prices soared as much as 10% higher the next day.
- [By Chris Lange]
HP Inc. (NYSE: HPQ) reported fiscal second-quarter financial results after markets closed Wednesday. The company said that it had $0.40 in earnings per share (EPS) and $12.39 billion in revenue, versus consensus estimates from Thomson Reuters that called for $0.39 in EPS and $11.88 billion in revenue. The same period from last year had $0.41 in EPS and $11.59 billion in revenue.
- [By Peter Graham]
The Q4 2016 earnings report for small cap 3D printer stock ExOne Co (NASDAQ: XONE) is scheduled for after the marketcloses onThursday (March 16th). 3D printer stocks had their day in the sun a fewyears ago, buthave been disappointing investors eversincethe 3Dbubble burst whileHP Inc (NYSE: HPQ) entering the printer market with its Jet Fusion 3D adds further headwinds. However,3D printershares appear to have stabilized as the short interest has largely been cleared out.
- [By Alex Cho]
That being the case, it wouldnt take substantial market share gains for AMD to reverse the multi-year decline in its processor business, as performance/watt is what will drive adoption from key PC makers like Dell, HP Inc (NYSE:HPQ)and Lenovo. AMD hasnt been very competitive in the MPU (microprocessor unit) segment for quite a while, but given the recent node shift to 14nm FinFET over at GlobalFoundries, and mention of new architecture by AMD earlier this year at COMPUTEX Taiwan, I get the impression that performance of Summit Ridge, i.e. Zen will match Skylake and will perhaps come in slightly slower than Kaby Lake.
great stocks to own: Coherus BioSciences, Inc.(CHRS)
- [By Lisa Levin] Gainers
Red Robin Gourmet Burgers, Inc. (NASDAQ: RRGB) shares rose 18.4 percent to $68.65 in pre-market trading as the company reported upbeat results for its first quarter.
Jack in the Box Inc. (NASDAQ: JACK) shares rose 9.5 percent to $111.60 in the pre-market trading session after the company posted better-than-expected earnings for its second quarter. The company also disclosed that it has retained Morgan Stanley to evaluate potential alternatives for Qdoba.
Coherus Biosciences Inc (NASDAQ: CHRS) rose 9.8 percent to $24.20 in pre-market trading. Coherus BioSciences disclosed that it prevailed in ‘135 IPR decision.
Qiwi PLC (NASDAQ: QIWI) rose 8.1 percent to $21.49 in pre-market trading after reporting strong quarterly results.
Korea Electric Power Corporation (ADR) (NYSE: KEP) shares rose 7.9 percent to $20.00 in pre-market trading after dropping 4.33 percent on Tuesday
Target Corporation (NYSE: TGT) shares rose 7.5 percent to $58.60 in pre-market trading after the company reported stronger-than-expected results for its first quarter.
AngloGold Ashanti Limited (ADR) (NYSE: AU) rose 4.3 percent to $11.71 in pre-market trading after falling 0.09 percent on Tuesday.
Colgate-Palmolive Company (NYSE: CL) rose 4.1 percent to $74.53 in pre-market trading after the NY Post reported that the company might be up for sale for $100 per share.
Harmony Gold Mining Co. (ADR) (NYSE: HMY) rose 4 percent to $2.35 in pre-market trading after declining 1.74 percent on Tuesday.
Core Laboratories N.V. (NYSE: CLB) rose 3.6 percent to $109.00 in pre-market trading after gaining 0.39 percent on Tuesday.
Clovis Oncology Inc (NASDAQ: CLVS) rose 3.2 percent to $51.15 in pre-market trading. JP Morgan upgraded Clovis Oncology from Neutral to Overweight.
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.
- [By Ben Levisohn]
Today,Coherus BioSciences (CHRS) lost a patent case with AbbVie (ABBV) that would have allowed for a generic version of Humira. Citigroup’s Andrew Baum and Peter Verdult have the details:
Agence France-Presse/Getty Images
The Patent Trial and Appeal Boardjust announced that CHRSs IPR on the 166 Humira formulation patent was not instituted. We remind investors that Amgens IPR on the same 157 and 158 formulation patents were also not instituted. Any at risk launch on a formulation that potentially infringes 166, 157 or 158 would seem unlikely and carries a high risk thatAbbVie would attain a preliminary injunction. It is not clear whether either company could attempt launch with a formulation that does not infringe the patent estate. We note that Sandoz has uniquely not filed any IPR on any biosimilars. Sandoz has not announced the FDA has accepted their filing for their biosimilar adalimumab…We anticipate that the perceived historic relationship of the immunogenicity of Humira as it relates to dose stretching will form a key debate in the ongoing PTAB case…
Following the decision of the PTAB not to institute CHRS IPR on the 166 Humira formulation patent, we continue to anticipate that first likely launch of biosimilar adalimumab (Humira) in the US will be delayed until 2020, in line with our published forecasts and biosimilar model. We anticipate the open IPR hearings for the 135 dosing patent on Humira (filed by Boehringer and Coherus) to begin in Feb 2017 with the ruling in May. We rateAbbVie a Buy. We continue to prefer BUY rated Bristol-Myers Squibb (BMY), Eli Lilly (LLY) among the US names.
Shares of AbbVie have climbed 5.6% to $59.18 at 3:05 p.m. today, while Coherus BioSciences has tumbled 11% to $25.18,Bristol-Myers Squibb has gained 3% to $52.56, andEli Lilly has risen 1.7% to $73.70.
- [By Lisa Levin]
Coherus Biosciences Inc (NASDAQ: CHRS) shares shot up 23 percent to $13.70 after the company announced plans to raise up to $150 million in a private placement.
great stocks to own: Trevena, Inc.(TRVN)
- [By Chris Lange]
Trevena Inc. (NASDAQ: TRVN) reported positive results from two late-stage clinical trials that work to treat post-surgical pain. The company intends to submit these results to the FDA for a marketing approval agreement in the fourth quarter. Previously, oliceridine was approved for a breakthrough designation by the agency.
- [By Lisa Levin]
Trevena Inc (NASDAQ: TRVN) shares dropped 36 percent to $4.55 despite a positive development in Phase 3 trials. Trevena announced positive top-line results from ongoing Phase 3 trials called "APOLLO-1" and "APOLLO-2." The studies evaluated the safety of Trevena's oliceridine therapy in patients for 48 hours following bunionectomy and 24 hours following abdominoplasty.
- [By Paul Ausick]
Trevena Inc. (NASDAQ: TRVN) dropped about 6.3% Thursday, to post a new 52-week low of $3.70 after closing at $3.95 on Wednesday. The stock’s 52-week high is $9.73. Volume was nearly 5 times the daily average of around 700,000 shares. The company’s pain-killing drug got mixed results in a trial result reported Tuesday.